Skip to main content

AGIO

Stock
Health Care
Biotechnology

Performance overview

AGIO Price
Price Chart

Forward-looking statistics

Beta
1.42
Risk
56.18%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development planĀ for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Company info

SectorHealth Care
IndustryBiotechnology
Employees634
Market cap$2.7B

Fundamentals

Enterprise value$1.1B
Revenue$37.0M
Revenue per employee—
Profit margin1798.26%
Debt to equity3.61

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$11.54
Dividend per share—
Revenue per share$0.65
Avg trading volume (30 day)$23M
Avg trading volume (10 day)$22M
Put-call ratio—

Macro factor sensitivity

Growth+3.7
Credit+3.0
Liquidity+0.1
Inflation-0.5
Commodities+1.0
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio-5.93
Price to sales56.41
P/E Ratio-5.93
Enterprise Value to Revenue29.32
Price to book1.42

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last?

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research (July 10, 2025)
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to

Benzinga (August 1, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free